Liquid Biopsy for Cancer: Review and Implications for the Radiologist
The DOI matches its Crossref record; 95 of the 95 references it cites were found in a registry or an index.
Abstract
Imaging and image-guided procedures play an imperative role in the screening, diagnosis, and surveillance of cancer. Although emerging imaging techniques now enable more precise molecular characterization of tumors, multigenetic tumor profiling for targeted therapeutic selection remains limited to direct tissue acquisition. Even in the context of targeted therapy, tumors adapt to acquire resistance. This necessitates serial monitoring, traditionally through tissue acquisition, to identify the molecular mechanism of resistance and to guide second-line therapy. An alternative to tissue acquisition is the collection of circulating tumor markers such as cell-free nucleic acids and circulating tumor cells in the peripheral blood. This noninvasive diagnostic approach is referred to as the liquid biopsy. The liquid biopsy is currently used clinically for therapeutic guidance when tissue acquisition is impossible or when the specimen is inadequate. It is also being studied in the context of screening, diagnosis, and surveillance. As cancer treatment continues to move toward a focus on precision medicine, this developing technology may alter and/or augment the role of imaging in the management of cancer. This review aims to outline the use of liquid biopsy in cancer and its potential impact on diagnostic imaging and image-guided procedures.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“As a highly sensitive liquid biopsy methodology, NGS-based ctDNA detection can enable the identification of tumor relapse earlier than traditional radiological examinations, thereby facilitating prompt treatment decisions.8, 9, 10”
From Tumor-informed deep sequencing of ctDNA detects minimal residual disease and predicts relapse in osteosarcoma (2024) · cites this paper as [8]
Citations
Cites
Reduced Lung-Cancer Mortality with Low-Dose Computed Tomographic Screening
The National Lung Screening Trial Research Team (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1102873 · Cited by 11,064
The basics of epithelial-mesenchymal transition
Kalluri, R., & Weinberg, R. A. (2009) · Journal of Clinical Investigation · doi:10.1172/jci39104 · Cited by 10,196
Detection of Circulating Tumor DNA in Early- and Late-Stage Human Malignancies
Bettegowda, C., Sausen, M., Leary, R. J., Kinde, I., Wang, Y., Agrawal, N., Bartlett, B. R., Wang, H., Luber, B., Alani, R. M., et al. (2014) · Science Translational Medicine · doi:10.1126/scitranslmed.3007094 · Cited by 5,067
Detection and localization of surgically resectable cancers with a multi-analyte blood test
Cohen, J. D., Li, L., Wang, Y., Thoburn, C., Afsari, B., Danilova, L., Douville, C., Javed, A. A., Wong, F., Mattox, A., et al. (2018) · Science · doi:10.1126/science.aar3247 · Cited by 2,783
Circulating mutant DNA to assess tumor dynamics
Diehl, F., Schmidt, K., Choti, M. A., Romans, K., Goodman, S., Li, M., Thornton, K., Agrawal, N., Sokoll, L., Szabo, S. A., et al. (2008) · Nature Medicine · doi:10.1038/nm.1789 · Cited by 2,734
Screening for Lung Cancer: U.S. Preventive Services Task Force Recommendation Statement
Moyer, V. A., & on behalf of the U.S. Preventive Services Task Force* (2014) · Annals of Internal Medicine · doi:10.7326/m13-2771 · Cited by 2,632
Allard, W. J., Matera, J., Miller, M. C., Repollet, M., Connelly, M. C., Rao, C., Tibbe, A. G. J., Uhr, J. W., & Terstappen, L. W. M. M. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-0378 · Cited by 2,542
Panitumumab–FOLFOX4 Treatment and RAS Mutations in Colorectal Cancer
Douillard, J.-Y., Oliner, K. S., Siena, S., Tabernero, J., Burkes, R., Barugel, M., Humblet, Y., Bodoky, G., Cunningham, D., Jassem, J., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1305275 · Cited by 2,263
An ultrasensitive method for quantitating circulating tumor DNA with broad patient coverage
Newman, A. M., Bratman, S. V., To, J., Wynne, J. F., Eclov, N. C. W., Modlin, L. A., Liu, C. L., Neal, J. W., Wakelee, H. A., Merritt, R. E., et al. (2014) · Nature Medicine · doi:10.1038/nm.3519 · Cited by 2,220
de Bono, J. S., Scher, H. I., Montgomery, R. B., Parker, C., Miller, M. C., Tissing, H., Doyle, G. V., Terstappen, L. W. W. M., Pienta, K. J., & Raghavan, D. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-0872 · Cited by 2,182
Research works printed but not linked: 4
- Hricak H, 2016, Radiology 2018, 286, 764
- Sabari JK, 2018, J Natl Cancer Inst
- Ferry-Galow KV, 2018, J Oncol Pract, JOP1800092
- Tempero MA, 1987, Cancer Res, 47, 5501
Cited by
Recent advancements in optical biosensors for cancer detection
Kaur, B., Kumar, S., & Kaushik, B. K. (2022) · Biosensors and Bioelectronics · doi:10.1016/j.bios.2021.113805 · Cited by 433
Breast Cancer Screening for Women at Higher-Than-Average Risk: Updated Recommendations From the ACR
Monticciolo, D. L., Newell, M. S., Moy, L., Lee, C. S., & Destounis, S. V. (2023) · Journal of the American College of Radiology · doi:10.1016/j.jacr.2023.04.002 · Cited by 290
Surface Plasmon Resonance (SPR) Sensor for Cancer Biomarker Detection
Das, S., Devireddy, R., & Gartia, M. R. (2023) · Biosensors · doi:10.3390/bios13030396 · Cited by 223
“Plasma, saliva, urine, serum, and blood can all be used to detect these components [63].”
BackgroundNovel Approaches to Screening for Breast Cancer
Mann, R. M., Hooley, R., Barr, R. G., & Moy, L. (2020) · Radiology · doi:10.1148/radiol.2020200172 · Cited by 167
Small extracellular vesicles in cancer
Abhange, K., Makler, A., Wen, Y., Ramnauth, N., Mao, W., Asghar, W., & Wan, Y. (2021) · Bioactive Materials · doi:10.1016/j.bioactmat.2021.03.015 · Cited by 131
Metadata
- Authors
- Underwood, J. J., Quadri, R. S., Kalva, S. P., Shah, H., Sanjeeviah, A. R., Beg, M. S., & Sutphin, P. D.
- Affiliations
- University of North Texas Health Science Center (US)
- ORCID
- Venue
- Radiology
- Published
- 2020-01
- Volume
- 294
- Issue
- 1
- Pages
- 5-17
- ISSN
- 0033-8419 (ISSN-L)
- 1527-1315
- OpenAlex
- W2990366580
- Cited by
- 87
- References
- 95
- Citations by year
- 2026: 7 · 2025: 14 · 2024: 13 · 2023: 20 · 2022: 19 · 2021: 10 · 2020: 4
- FWCI
- 0.79
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Radiology (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Genomics and Diagnostics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Health Sciences › Medicine › Oncology › Cancer Diagnosis and Treatment
- Keywords
- liquid biopsy, circulating tumor DNA, circulating tumor cells, cancer screening, cancer diagnosis, cancer surveillance, targeted therapy, treatment resistance, molecular profiling, precision medicine, image-guided interventions, non-invasive diagnosis
- MeSH terms
- Liquid Biopsy, Humans, Neoplasms
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Liquid Biopsy for Cancer: Review and Implications for the Radiologist. https://app.cochat.ai/papers/10.1148/radiol.2019182584
- The paper
- Underwood, J. J., Quadri, R. S., Kalva, S. P., Shah, H., Sanjeeviah, A. R., Beg, M. S., & Sutphin, P. D. (2020). Liquid Biopsy for Cancer: Review and Implications for the Radiologist. Radiology. https://doi.org/10.1148/radiol.2019182584
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.